Introduction {#Sec1}
============

Peripheral T cell lymphomas are rare \[[@CR1]\], accounting for 5--10 % of all non-Hodgkin lymphomas in Western countries \[[@CR2]\]. The most frequent entities according to the WHO classification are peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), extranodal NK/T cell lymphoma and anaplastic large cell T cell lymphoma (ALCL) with and without expression of anaplastic lymphoma kinase (ALK) \[[@CR3]\].

Systemic PTCL follow an aggressive clinical course with significantly less favourable outcome than aggressive B cell lymphomas \[[@CR4], [@CR5]\]. The International Prognostic Index (IPI) \[[@CR6]\] also predicts outcome in PTCL; however, even in the best category, the overall survival (OS) at 5 years is only 50 % \[[@CR2]\], excluding patients with ALK + ALCL with an excellent outcome in the IPI 0/1 categories \[[@CR7]\].

Treatment with CHOP-like protocols results in overall response rates of 60--70 % but unsatisfactory long-term remissions \[[@CR7]\] and a median 5-year OS of only 32 % \[[@CR3]\]. Dose-dense CHOP-14 therapy with inclusion of etoposide was recently shown in a retrospective analysis to improve outcome in patients \<60 years with normal LDH \[[@CR8]\], yielding a 3-year event-free survival (EFS) of 71 versus 51 % for conventional CHOP in ALK + ALCL patients. Although currently recommended as consolidation for high-risk patients in first remission, contradictory results are reported for up-front dose escalation followed by autologous stem cell transplantation (ASCT). Several trials show OS rates comparable to those with conventional regimens, in particular, when ALK + ALCL are excluded \[[@CR9]--[@CR11]\]. Other authors report OS rates of 49 % at 5 years and of 59 % at 4 years \[[@CR12], [@CR13]\]. In three prospective trials on up-front ASCT in PTCL, 3-year OS rates of 73 \[[@CR14]\], 48 \[[@CR15]\] and 56 % \[[@CR16]\] were observed.

The monoclonal antibody alemtuzumab targeting the CD52 molecule on B and T cells \[[@CR17]\] is an attractive candidate for treatment optimization. Although CD52 expression on malignant T cells varies considerably \[[@CR18]\], this antibody showed promising activity in trials of various T cell lymphomas \[[@CR19]--[@CR22]\]. However, its use is complicated by severe opportunistic infections. Reduction of dose and treatment duration has been shown to decrease these complications without compromising the antitumor effect \[[@CR23]\].

The rationale of the prospective multicenter phase II DSHNHL 2003--1 study was therefore to combine CHO(E)P-14, an effective chemotherapy for PTCL, with alemtuzumab. The antibody was given to patients in complete response/unconfirmed complete response (CR/CRu) or partial response (PR) after chemotherapy as a short consolidation course to avoid excessive toxicity.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

The study (NCT Nr. 01806337) was conducted according to the Declaration of Helsinki and approved by the ethics committees of the participating institutions. Patients were enrolled between July 2003 and July 2006 after written informed consent. Inclusion criteria were age 18--70 years, Eastern Cooperative Oncology Group (ECOG) 0--3, previously untreated aggressive PTCL (all IPI), histology of PTCL-NOS (including the lymphoepitheloid Lennert's variant), AITL, ALK-ALCL and enteropathy-associated intestinal T cell lymphomas (EATL). ALK + ALCL and extranodal T/NK cell lymphomas were excluded as well as patients with major organ dysfunctions other than lymphoma-related, bone marrow infiltration \>25 % (quantified by flow cytometry in case of morphological positivity), a history of tuberculosis and overt cytomegalovirus (CMV)-infection, active hepatitis, HIV-positivity, other uncontrolled infections, additional neoplasms and previous radio-chemotherapy. Histological diagnosis was reviewed by a panel of expert haematopathologists.

Treatment schedule {#Sec4}
------------------

Staging included physical examination, routine laboratory testing, computed tomography scan of neck, chest and abdomen and bone marrow biopsy. Bulky disease was defined as the presence of a tumour mass ≥7.5 cm. A planned complete restaging repeating all of the primary investigations (bone marrow biopsy only in case of involvement) was performed after six chemotherapy cycles (restaging 1). The International Workshop criteria were used for response assessment \[[@CR24]\]. After prephase treatment (prednisolone/vincristine), patients \<60 years received 6 cycles of CHOEP-14, patients \>60 years 6 × CHOP-14 \[[@CR25]\], supported by pegfilgrastim 6 mg. Patients with no change (NC) or progression (PRO) went off study. Patients with CR/CRu or PR after chemotherapy received alemtuzumab consolidation (133 mg over 4 weeks) starting 3--6 weeks after the end of chemotherapy. The first three doses were administered intravenously on days 1--3 with dose escalation (3, 10, 30 mg; premedication with clemastin, paracetamol, prednisolone), the following three doses (30 mg) subcutaneously once per week. Prophylaxis against *Pneumocystis jirovecii* and herpes infections was mandatory and was continued until CD4-cells \>200/μl. Patients with positive CMV serology were monitored weekly (pp65, CMV-PCR). Four weeks after completion of the consolidation, a restaging was performed as described above (restaging 2). Patients not receiving alemtuzumab due to reasons other than insufficient chemotherapy response also underwent restaging 2. During the follow-up visits (years 1--2: every 3 months, years 3--5: every 6 months), patients were monitored by physical examination, routine laboratory testing and CT scans (every 6 months).

Statistical analysis {#Sec5}
--------------------

Primary endpoint was the feasibility of alemtuzumab consolidation after a full course of CHO(E)P with assessment of relative dose and toxicity. Secondary endpoints were rate of remission, primary progression, number of patients receiving alemtuzumab, therapy-related mortality, EFS and OS, calculated as the time from registration to the first reported event (PRO, initiation of salvage therapy, additional (unplanned) treatments, relapse or death of any cause) or censored at the most recent assessment date. The analysis was planned as intention-to-treat (ITT) with an additional per protocol analysis (PP) of patients with fulfilled inclusion criteria. The trial was designed to include at least 24 patients with reference diagnosis PTCL-NOS/AITL, receiving alemtuzumab after a full course of chemotherapy. Forty-one patients were registered to allow reliable estimations of the primary endpoint for patients receiving alemtuzumab and to estimate e.g., the complete remission rate for patients with alemtuzumab with a precision of ±18 %. Survival curves were compared with log-rank tests. Relative doses were estimated according to Kaplan--Meier \[[@CR25]\]. The significance level was *p* = 0.050. Statistical analyses were done with SPSS PASW 18.

Results {#Sec6}
=======

Patients' characteristics {#Sec7}
-------------------------

Forty-one patients were recruited from 20 institutions and included in the ITT analysis (Table [1](#Tab1){ref-type="table"}). A PP analysis was performed on 37 patients excluding those with incorrect reference histologies: three ALK + ALCL and one extranodal NK cell lymphoma. A considerable number presented with unfavourable prognostic features. Stage III/IV and elevated LDH were more often found in the older cohort. The latter was also more frequent in patients who later did not qualify for alemtuzumab consolidation, whereas other risk factors, such as bulky disease and bone marrow involvement, were present at a higher rate in the alemtuzumab group.Table 1Patients' characteristics (ITT population)≤60 years (*n* = 27)\>60 years (*n* = 14)Total (*n* = 41)Male18 (66.7 %)8 (57.1 %)26 (63.4 %)Female9 (33.3 %)6 (42.9 %)15 (36.6 %)Age, median (range)50 (19, 59)67 (63, 70)55 (19, 70)Age \>60 years14 (34.1 %)LDH \> UNV9 (33.3 %)11 (78.6 %)20 (48.8 %)ECOG \> 11 (3.7 %)2 (14.3 %)3 (7.3 %)ECOG 015 (55.6 %)3 (21.4 %)18 (43.9 %)ECOG 111 (40.7 %)9 (64.3 %)20 (48.8 %)ECOG 21 (3.7 %)2 (14.3 %)3 (7.3 %)ECOG 3/40 (0.0 %)0 (0.0 %)0 (0.0 %)Stage III/IV14 (51.9 %)12 (85.7 %)26 (63.4 %)Stage I6 (22.2 %)1 (7.1 %)7 (17.1 %)Stage II7 (25.9 %)1 (7.1 %)8 (19.5 %)Stage III7 (25.9 %)8 (57.1 %)15 (36.6 %)Stage IV7 (25.9 %)4 (28.6 %)11 (26.8 %)Extranodal involvement \> 1^a^5 (18.5 %)2 (14.3 %)7 (17.1 %)Extranodal involvement^a^11 (40.7 %)8 (57.1 %)19 (46.3 %)IPI^a^ 0, 116 (59.3 %)0 (0.0 %)16 (39.0 %)28 (29.6 %)2 (14.3 %)10 (24.4 %)33 (11.1 %)11 (78.6 %)14 (34.1 %)4, 50 (0.0 %)1 (7.1 %)1 (2.4 %)Bulky disease4 (14.8 %)1 (7.1 %)5 (12.2 %)B symptoms^b^9 (34.6 %)7 (50.0 %)16 (40.0 %)BM involvement4 (14.8 %)2 (14.3 %)6 (14.6 %)Histopathology PTCL-unspecified (NOS)21 (51.2 %) AITL11 (26.8 %) Lennert's variant3 (7.3 %) ALCL, ALK+^c^3 (7.3 %) ALCL, ALK−1 (2.4 %) Extranodal NK/T^c^1 (2.4 %) Enteropathy-associated1 (2.4 %)*PTCL (NOS)* peripheral T cell lymphoma not otherwise specified, *AITL* angioimmunoblastic T cell lymphoma, *ALCL* anaplastic large cell lymphoma, *ALK* anaplastic lymphoma kinase, *NK* natural killer^a^BM involvement is counted as extranodal involvement^b^One missing value^c^Reference histology not meeting the inclusion criteria according to primary pathology

Treatment feasibility {#Sec8}
---------------------

The median duration of the first 5 cycles of CHO(E)P-14 was only slightly longer than planned (77 versus 70 days) with median relative doses of 99.4, 99.8 and 100 % for cyclophosphamide, doxorubicin and etoposide. Dose reduction of vincristine was more frequent in the cohort \>60 years, where 24.5 % received less than the complete dose of 6 × 2 mg (6.8 % for \<60 years). In the majority of the patients (70.8 %), growth factor support was performed with 6 mg pegfilgrastim according to the study protocol, in some cases substituted by equivalent doses of other G-CSF preparations (23 %, type of G-SCF unknown in 6.2 %) without any difference between the age groups. Thirty-five patients (85.4 %) received all of the planned six chemotherapy cycles (81.5 % \< 60 versus 92.9 % \>60 years). In six patients, chemotherapy was stopped earlier, predominantly due to early progression (see below and Fig. [1](#Fig1){ref-type="fig"}). Therapy with alemtuzumab was started between days 22 and 59 after the end of chemotherapy (median, 34 days) with a median duration of 23 days. Most of the 29 patients qualifying for alemtuzumab (see below) received the planned total dose of 133 mg at the projected time points. Reasons for dose reduction were CMV reactivation (1), severe skin reaction (1) and progression (1). A higher dose was given accidentally to one patient (226 mg).Fig. 1Treatment schedule and clinical course (*PRO* progressive disease, *NC* no change, for explanation of "other" see "[Treatment response](#Sec9){ref-type="sec"}")

Treatment response {#Sec9}
------------------

The rate of CR/CRu or good PR after chemotherapy (restaging 1) was 80.5 % (33/41 patients). Eight patients (19.5 %) did not respond sufficiently, four of them showing PRO or NC either early during chemotherapy or shortly afterwards (Fig. [1](#Fig1){ref-type="fig"}). They continued treatment off study with various salvage protocols, from conventional salvage regimens to allogeneic stem cell transplantation.

Altogether, 12 patients (29.3 %) did not qualify for alemtuzumab (Fig. [1](#Fig1){ref-type="fig"}). Apart from the eight with insufficient response, the reasons were patient's refusal (1), severe skin exanthema after chemotherapy (1) and reference histology of ALK + ALCL (1). One patient with stage IA disease chemotherapy achieved a CR after three cycles of CHOEP and was treated with involved field irradiation.

The remaining 29 patients (70.7 %) received alemtuzumab consolidation. Among them were two with the retrospective diagnosis of ALK + ALCL and one extranodal NK/T, nasal type, which was unknown at the time of response evaluation after chemotherapy. There was a 60.9 % remission rate at restaging 2 after completion of the whole therapy (ITT, Table [2](#Tab2){ref-type="table"}) with 24 patients still in CR/CRu and one patient remaining in the same status of good PR as after induction chemotherapy. Four patients with CR/Cru or PR at restaging 1 had meanwhile relapsed, two of them under or immediately after alemtuzumab, two of them without (refusal, skin reaction, see above). Considering the whole observation time, relapses (ITT) tended to be more frequent in patients \>60 years and there was a non-significant trend to better EFS and OS at 3 years for patients ≤60 years (Fig. [2a, b](#Fig2){ref-type="fig"}). In the PP analysis, the EFS at 3 years was 31.4 % \[16.3; 46.5 % (95 % confidence interval)\] and the OS was 63.9 % \[48.2; 79.6 %\], thus not essentially different from the complete ITT population (Fig. [2c, d](#Fig2){ref-type="fig"}). There was no parameter segregating patients with a good response to chemotherapy and consecutive alemtuzumab consolidation from those with the opposite outcome. Neither sex, age, histology nor the established prognostic markers, such as LDH, IPI, extranodal involvement, were essentially different. For these selected patients who actually received alemtuzumab, the rates for EFS (42.4 % \[95 % CI, 23.8--61.0 %\]) and OS (75.1 % \[95 % CI, 59.0--91.2 %\]) were clearly higher than in the whole cohort.Table 2Treatment outcome (ITT population, median observation time 46 months)≤60 years (*n* = 27)\>60 years (*n* = 14)Total (*n* = 41)Response after completion of therapy^b^ CR/CRu16 (59.3 %)8 (57.1 %)24 (58.5 %)\[38.8 %; 77.6 %\]^a^\[28.9 %; 82.3 %\]^a^\[42.1 %; 73.7 %\]^a^ PR0 (0.0 %)1 (7.1 %)1 (2.4 %)\[0.0 %; 12.8 %\]^a^\[0.2 %; 33.9 %\]^a^\[0.1 %; 12.9 %\]^a^ NC4 (14.8 %)0 (0.0 %)4 (9.8 %)\[4.2 %; 33.7 %\]^a^\[0.0 %; 23.2 %\]^a^\[2.7 %; 23.1 %\]^a^ PRO7 (25.9 %)5 (35.7 %)12 (29.3 %)\[11.1 %; 46.3 %\]^a^\[12.8 %; 64.9 %\]^a^\[16.1 %; 45.5 %\]^a^ Relapse in CR/CRu^c^5/16 (31.3 %)4/8 (50.0 %)9/24 (37.5 %)\[11.0 %; 58.7 %\]^a^\[15.7 %; 84.3 %\]^a^\[18.8 %; 59.4 %\]^a^Survival (36 months) EFS38.5 %21.4 %32.3 %\[19.5 %; 57.5 %\]^a^\[0.0 %; 43.0 %\]^a^\[17.6 %; 47.0 %\]^a^ OS73.3 %41.7 %62.4 %\[56.2 %; 90.4 %\]^a^\[15.2 %; 68.2 %\]^a^\[47.3 %; 77.5 %\]^a^Deaths Total11/27 (40.7 %)8/14 (57.1 %)19/41 (46.3 %) Lymphoma-related7/11 (63.6 %)6/8 (75.0 %)13/19 (68.4 %) Salvage therapy-related2/11 (18.2 %)1/8 (12.5 %)3/19 (15.8 %) Potentially therapy-related1/8 (12.5 %)1/19 (5.3 %) Sec. neoplasm1/11 (9.1 %--1/19 (5.3 %) Unknown1/11 (9.1 %)--1/19 (5.3 %)^a^95 % confidence interval^b^Response after the complete sequence of therapy, including all patients, also those having not received alemtuzumab due to NC/PRO under chemotherapy or other reasons (see "[Treatment response](#Sec9){ref-type="sec"}")^c^All patients classified as having CR/Cru at restaging 2 after the complete sequence of therapyFig. 2Survival (ITT population, *n* = 41) **a** EFS according to age groups. **b** OS according to age groups. **c** EFS and OS in the whole population. **d** EFS and OS in patients with alemtuzumab consolidation (*n* = 29)

After a median observation time of 46 months, 19 (46.3 %) patients have died. Death was mostly due to lymphoma (13) and/or salvage therapy complications (3). In two patients, lymphoma was complicated by cardiovascular disease and chronic pseudomembranous colitis following CHOEP chemotherapy requiring surgical intervention. There were three additional deaths, the reason for one of them being unknown; however, most probably lymphoma-related since the patient was reported to have relapsed. The two other patients are discussed below.

Treatment toxicity {#Sec10}
------------------

Adverse events during the initial chemotherapy were comparable to those observed in earlier studies with CHO(E)P-14. Haematotoxicity was the predominant complication with slightly higher rates in the younger group due to addition of etoposide.

The application of alemtuzumab was generally well tolerated. One patient suffered from a severe skin reaction leading to dose reduction, the other patients did not experience any acute grade 3--4 toxicities. Leukocytopenia was the main haematological toxicity. Leukocyte counts \<2,000/μl were observed in three patients, two requiring G-CSF support. There was no severe thrombocytopenia or anaemia. Four patients suffered from grades 3--4 infections between 1 and 6 weeks after the last alemtuzumab application: three pneumonias due to *Aspergillus* spp. and *Candida albicans* (1) and CMV (2). The fourth patient presented with Gram-negative sepsis following tooth extraction without antibiotic prophylaxis. There were also several less severe infections: *Herpes zoster* infection 3 weeks after alemtuzumab (1), asymptomatic CMV reactivation during alemtuzumab (3) and fever of unknown origin (1). All patients recovered with appropriate therapy. Eight months after the end of alemtuzumab, there was one fatal course of infection which was potentially treatment-related. This 70-year-old patient, initially with stage IV PTCL-NOS and splenic involvement, experienced prolonged leukopenia following alemtuzumab. Two months after the last restaging, reported as CR, he died from fungal pneumonia with CMV reactivation complicated by cardiac and hepatic failure. One patient developed acute myeloid leukemia (AML) 20 months after completion of therapy with CHOEP and alemtuzumab while still in CR. He died from this disease 13 months later. EBV-related lymphomas were not reported.

Discussion {#Sec11}
==========

We could demonstrate that alemtuzumab consolidation after a complete chemotherapy for PTCL was feasible, and nearly all patients received the planned dose of 133 mg within the projected time frame. Grades 3--4 infections were seen in four patients; however, all of them were manageable and with complete recovery. Of note, CMV-pneumonias occurred in spite of close clinical follow-up and CMV monitoring. One of these patients showed grade 3 leukopenia requiring prolonged support with G-CSF and relapsed after several months. The second, still in CR after 46 months, had excessively low CD4-counts remaining \<200/μl for almost 1 year. While there is no obvious correlation between relapse and infections in these two cases, the third case of a mixed fungal pneumonia suggests that profound immunosuppression due to disease progression may have contributed to this severe complication. Although in CR at restaging 1 after chemotherapy, the patient who initially had a widely disseminated EATL experienced a fulminant relapse only 2 weeks after recovery from the pneumonia and died shortly afterwards.

No treatment-related death occurred during alemtuzumab application and until 8 months later. There was one fatal course of a 70-year-old patient who died from pneumonia 8 months after the end of therapy. Although persistently low leukocyte counts have certainly contributed to the severe infection, immunosuppression by an incipient lymphoma relapse cannot be excluded. The patient showed high-risk criteria for relapse, the last staging was 2 months ago and a postmortem work-up was not done. Thus, it is difficult to decide whether this death represents a late complication of therapy or is due to the underlying illness.

As another potential late treatment effect, we observed one case of AML in a younger patient receiving CHOEP-14 and alemtuzumab. Since etoposide is known to increase the incidence of secondary AML, this was probably a consequence of chemotherapy rather than of alemtuzumab.

Other trials chose a strategy of concomitant chemotherapy and alemtuzumab. Combination of either CHOP-28 or −21 with alemtuzumab (30 mg/cycle) led to frequent severe infections with two treatment-related deaths \[[@CR26], [@CR27]\]. The added effect of alemtuzumab with a total dose almost twice as high as in our study may explain the distinctly higher rate of serious infections. Combination of alemtuzumab (70 mg/cycle) with a fludarabine-containing regimen induced even higher infectious toxicities and six treatment-related deaths \[[@CR28]\]. Notably, two cases of EBV-associated lymphoproliferative disease (LPD) were observed several months after therapy. The same phenomenon was encountered in the HOVON study \[[@CR29]\], combining CHOP-14 with a very high dose of alemtuzumab (90 mg/cycle). Despite the rather long observation period, there was no such event in our study. This suggests that the total dose of alemtuzumab and/or the timing of alemtuzumab application is critical in this regard.

The potential influence of alemtuzumab on the treatment outcome is difficult to assess. The higher EFS and OS rates (42.4 and 75.1 %) in our alemtuzumab cohort may only reflect the selection effect after omission of those patients who did not respond sufficiently to the initial chemotherapy. Interestingly, a recent study of the GOELAMS group observed similar rates with 41 % EFS at 2 years after CHOP-21 alone \[[@CR30]\].

Nevertheless, the high overall remission rates achieved by high alemtuzumab doses concomitant to chemotherapy, ranging between 63 and 90 % \[[@CR26]--[@CR29]\], suggest an added effect. They are higher than in the present study. However, presumably due to the increased rate of side effects, the outcome regarding survival is not essentially different. A 2-year OS and EFS of 53 and 48 % \[[@CR26]\] as well as of 55 and 27 % \[[@CR29]\] were reported for 30 and 90 mg alemtuzumab per chemotherapy cycle, while OS and EFS in our study were 62.4 and 32.3 % at 3 years.

Surprisingly, this is more or less within the same range as observed with myeloablative protocols \[[@CR14], [@CR15]\] although the cytotoxic dose of chemo- and/or radiotherapy in these studies was much higher and the patients clearly younger. Recently, the Nordic Lymphoma Group has reported the final results of the NGT-T-01 trial \[[@CR16]\], investigating dose-dense CHO(E)P followed by high-dose chemotherapy and ASCT in treatment-naïve PTCL patients. Although OS rates are confounded by secondary regimens up to allogeneic stem cell transplantation, the 3-year OS (56 %) was not higher than in our study. The 3-year-EFS (32.3 %) used as a secondary endpoint in our study is difficult to compare with TTF and PFS rates since it is based on different criteria. However, the 3-year TTF of 41 % in the NGT-T-01 trial seems promising and may be explained by the relatively high amount of included ALK-ALCL (19 versus 2.4 % in our study), anaplastic histology being associated with significantly better outcome.

We conclude that CHO(E)P-14 followed by a short course of alemtuzumab consolidation is a feasible therapeutic option. Infectious complications are partially severe but mostly manageable and require particular attention. Due to the design of the study, the data do not allow the assessment of the alemtuzumab effect on treatment outcome. However, although representing a selected cohort with favourable characteristics, remission and survival rates in those patients receiving the complete immunochemotherapy are encouraging and comparable to those of more intensive regimens. To definitely clarify if and to what extent the different biological anti-tumour approach of alemtuzumab contributes to the therapeutic outcome, the results of randomized studies such as the current intergroup ACT trials are to be awaited.
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